COMMUNIQUÉS West-GlobeNewswire

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F
23/05/2025
Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, [...]
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
23/05/2025
IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment [...]
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
23/05/2025
PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies [...]
Boundless Bio Announces Portfolio Prioritization and Runway Extension
23/05/2025
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through [...]
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
23/05/2025
WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced a planned expansion of TVGN 489’s target population to include patients 65 and older. As [...]
Cross Medical Group Introduces HydraFacial Treatments for Advanced Skin Rejuvenation
23/05/2025
The Philadelphia Area Team is Offering a New, Highly Customizable Skin Resurfacing Option Starting This Spring PHILADELPHIA and VILLANOVA, Pa., May 23, 2025 (GLOBE NEWSWIRE) -- Cross Medical Group is pleased to announce [...]
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.
23/05/2025
TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“ MediPharm ”, the “ Company ”, or “ we ”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its [...]
Transactions of Managers and Closely Associated Persons
23/05/2025
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 95,000 shares in [...]
Mind Body Peak Performance Rebrands to ‘High Performance Longevity’ Podcast, Integrating Biohacking with Ancestral Wisdom
23/05/2025
Austin, TX, May 23, 2025 (GLOBE NEWSWIRE) -- Outliyr, a performance health brand known for combining modern biohacking with ancestral wisdom, has rebranded its podcast—formerly Mind Body Peak Performance —as High [...]
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
23/05/2025
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, [...]
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
23/05/2025
Positive recommendation based on phase III INAVO120 data showing Itovebi TM (inavolisib) in combination with palbociclib and fulvestrant more than doubled progression-free survival in the first-line setting 1 The [...]
Tilray Medical introduit Good Supply, la marque emblématique de cannabis canadienne, en Allemagne
23/05/2025
NEUMÜNSTER, Allemagne, 23 mai 2025 (GLOBE NEWSWIRE) -- Tilray Medical (« Tilray »), une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique qui permet aux [...]
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting
23/05/2025
Study Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy Platform Abstract published on podium presentation that will [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
23/05/2025
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for [...]
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
23/05/2025
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of [...]
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
23/05/2025
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its [...]
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
23/05/2025
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, [...]
Safe Shot to Capitalize on Yerbae’s Strong Retail Presence & Distributor Network Following Acquisition
23/05/2025
Acquisition expected to increase Safety Shot annual revenue by 1000 percent over 2024 SCOTTSDALE, Ariz., May 23, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc . (Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a [...]
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
23/05/2025
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the [...]

Pages